The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives
Open accessAbstract
Osteoporosis is defined as low bone mineral density associated with skeletal fractures secondary to minimal or no trauma, most often involving the spine, the hip, and the forearm. The decrease in bone mineral density is the consequence of an unbalanced bone remodeling process, with higher bone resorption than bone formation. Osteoporosis affects predominantly postmenopausal women, but also older men. This chronic disease represents a considerable medical and socioeconomic burden for modern societies. The therapeutic options for the treatment of osteoporosis have so far comprised mostly antiresorptive drugs, in particular bisphosphonates and more recently denosumab, but also calcitonin and, for women, estrogens or selective estrogen receptor modulators. These drugs have limitations, however, in particular the fact that they lead to a low turnover state where bone formation decreases with the decrease in bone-remodeling activity. In this review, we discuss the alternative class of osteoporosis drugs, i.e. bone anabolics, their biology, and the perspectives they offer for our therapeutic armamentarium. We focus on the two main osteoanabolic pathways identified as of today: PTH, the only anabolic drug currently on the market; and activation of canonical Wnt signaling through inhibition of the endogenous inhibitors sclerostin and dickkopf1. Each approach is based on a different molecular mechanism, but most recent evidence suggests that these two pathways may actually converge, at least in part. Whereas recombinant human PTH treatment is being revisited with different formulations and attempts to regulate endogenous PTH secretion via the calcium-sensing receptor, antibodies to sclerostin and dickkopf1 are currently in clinical trials and may prove to be even more efficient at increasing bone mass, possibly independent of bone turnover. Each of these anabolic approaches has its own limitations and safety issues, but the prospects of effective anabolic therapy for osteoporosis are indeed bright.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287
LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00571-2 · Cited by 2,235
Self-citationEvidence for osteocyte regulation of bone homeostasis through RANKL expression
Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-hora, M., Feng, J. Q., Bonewald, L. F., Kodama, T., Wutz, A., Wagner, E. F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2452 · Cited by 1,778
High Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5
Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., & Lifton, R. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013444 · Cited by 1,591
Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
Matrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304
Dickkopf-1 is a master regulator of joint remodeling
Diarra, D., Stolina, M., Polzer, K., Zwerina, J., Ominsky, M. S., Dwyer, D., Korb, A., Smolen, J., Hoffmann, M., Scheinecker, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1538 · Cited by 1,298
Little, R. D., Folz, C., Manning, S. P., Swain, P. M., Zhao, S.-C., Eustace, B., Lappe, M. M., Spitzer, L., Zweier, S., Braunschweiger, K., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/338450 · Cited by 1,282
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
van Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L., de Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 892
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
Jilka, R. L. (2007) · Bone · doi:10.1016/j.bone.2007.03.017 · Cited by 720
Vahle, J. L., Sato, M., Long, G. G., Young, J. K., Francis, P. C., Engelhardt, J. A., Westmore, M. S., Ma, Y. L., & Nold, J. B. (2002) · Toxicologic Pathology · doi:10.1080/01926230252929882 · Cited by 695
Osteoporosis: impact on health and economics
Harvey, N., Dennison, E., & Cooper, C. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.260 · Cited by 687
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study
Richards, J., Rivadeneira, F., Inouye, M., Pastinen, T., Soranzo, N., Wilson, S., Andrew, T., Falchi, M., Gwilliam, R., Ahmadi, K., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60599-1 · Cited by 682
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., Lang, T. F., McGowan, J. A., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 614
Essential role of β-catenin in postnatal bone acquisition.
Holmen, S. L., Zylstra, C. R., Mukherjee, A., Sigler, R. E., Faugere, M.-C., Bouxsein, M. L., Deng, L., Clemens, T. L., & Williams, B. O. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501900200 · Cited by 584
Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S., & Oursler, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805133106 · Cited by 556
Deletion of a Single Allele of the Dkk1 Gene Leads to an Increase in Bone Formation and Bone Mass
Morvan, F., Boulukos, K., Clément-Lacroix, P., Roman, S. R., Suc-Royer, I., Vayssière, B., Ammann, P., Martin, P., Pinho, S., Pognonec, P., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060311 · Cited by 524
Self-citationClément-Lacroix, P., Ai, M., Morvan, F., Roman-Roman, S., Vayssière, B., Belleville, C., Estrera, K., Warman, M. L., Baron, R., & Rawadi, G. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505259102 · Cited by 520
Self-citationHigh Bone Mass in Mice Expressing a Mutant LRP5 Gene
Babij, P., Zhao, W., Small, C., Kharode, Y., Yaworsky, P. J., Bouxsein, M. L., Reddy, P. S., Bodine, P. V., Robinson, J. A., Bhat, B., et al. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.960 · Cited by 497
Lrp5 functions in bone to regulate bone mass
Cui, Y., Niziolek, P. J., MacDonald, B. T., Zylstra, C. R., Alenina, N., Robinson, D. R., Zhong, Z., Matthes, S., Jacobsen, C. M., Conlon, R. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2388 · Cited by 453
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia
Li, J., Sarosi, I., Cattley, R. C., Pretorius, J., Asuncion, F., Grisanti, M., Morony, S., Adamu, S., Geng, Z., Qiu, W., et al. (2006) · Bone · doi:10.1016/j.bone.2006.03.017 · Cited by 441
Ominsky, M. S., Vlasseros, F., Jolette, J., Smith, S. Y., Stouch, B., Doellgast, G., Gong, J., Gao, Y., Cao, J., Graham, K., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.14 · Cited by 414
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., Shen, Z., Patel, N., Tai, Y.-T., Chauhan, D., et al. (2009) · Blood · doi:10.1182/blood-2008-11-191577 · Cited by 399
Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
O'Brien, C. A., Plotkin, L. I., Galli, C., Goellner, J. J., Gortazar, A. R., Allen, M. R., Robling, A. G., Bouxsein, M., Schipani, E., Turner, C. H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002942 · Cited by 390
Bellido, T., Ali, A. A., Plotkin, L. I., Fu, Q., Gubrij, I., Roberson, P. K., Weinstein, R. S., O'Brien, C. A., Manolagas, S. C., & Jilka, R. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307444200 · Cited by 378
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
Bezooijen, R. L. V., Dijke, P. T., Papapoulos, S. E., & G.M. Löwik, C. W. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.02.005 · Cited by 367
Cosman, F., Eriksen, E. F., Recknor, C., Miller, P. D., Guañabens, N., Kasperk, C., Papanastasiou, P., Readie, A., Rao, H., Gasser, J. A., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.238 · Cited by 359
Ellies, D. L., Viviano, B., McCarthy, J., Rey, J.-P., Itasaki, N., Saunders, S., & Krumlauf, R. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060810 · Cited by 350
Ryu, J., Kim, H. J., Chang, E., Huang, H., Banno, Y., & Kim, H. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601430 · Cited by 317
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · Obstetrical and Gynecological Survey · doi:10.1097/00006254-200110000-00018 · Cited by 305
The calcium-sensing receptor in bone cells: A potential therapeutic target in osteoporosis
Marie, P. J. (2010) · Bone · doi:10.1016/j.bone.2009.07.082 · Cited by 281
Gowen, M., Stroup, G. B., Dodds, R. A., James, I. E., Votta, B. J., Smith, B. R., Bhatnagar, P. K., Lago, A. M., Callahan, J. F., DelMar, E. G., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9038 · Cited by 279
Kansara, M., Tsang, M., Kodjabachian, L., Sims, N. A., Trivett, M. K., Ehrich, M., Dobrovic, A., Slavin, J., Choong, P. F. M., Simmons, P. J., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37175 · Cited by 272
Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis
Finkelstein, J. S., Wyland, J. J., Lee, H., & Neer, R. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1703 · Cited by 265
Ominsky, M. S., Li, C., Li, X., Tan, H. L., Lee, E., Barrero, M., Asuncion, F. J., Dwyer, D., Han, C.-Y., Vlasseros, F., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.307 · Cited by 264
van Meurs, J. B. J. (2008) · JAMA · doi:10.1001/jama.299.11.1277 · Cited by 264
Eisman, J. A., Bone, H. G., Hosking, D. J., McClung, M. R., Reid, I. R., Rizzoli, R., Resch, H., Verbruggen, N., Hustad, C. M., DaSilva, C., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.212 · Cited by 244
Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity?
Karsdal, M. A., Martin, T. J., Bollerslev, J., Christiansen, C., & Henriksen, K. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070109 · Cited by 242
Li, X., Warmington, K. S., Niu, Q.-T., Asuncion, F. J., Barrero, M., Grisanti, M., Dwyer, D., Stouch, B., Thway, T. M., Stolina, M., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.182 · Cited by 231
Parathyroid hormone signaling through low-density lipoprotein-related protein 6
Wan, M., Yang, C., Li, J., Wu, X., Yuan, H., Ma, H., He, X., Nie, S., Chang, C., & Cao, X. (2008) · Genes & Development · doi:10.1101/gad.1702708 · Cited by 231
Ma, Y. L., Zeng, Q., Donley, D. W., Ste-Marie, L.-G., Gallagher, J. C., Dalsky, G. P., Marcus, R., & Eriksen, E. F. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060314 · Cited by 229
Dean, T., Vilardaga, J.-P., Potts, J. T., & Gardella, T. J. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0274 · Cited by 227
Guo, J., Liu, M., Yang, D., Bouxsein, M. L., Saito, H., Galvin, R. J. S., Kuhstoss, S. A., Thomas, C. C., Schipani, E., Baron, R., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.12.007 · Cited by 224
Self-citationLithium's effect on bone mineral density
Zamani, A., Omrani, G. R., & Nasab, M. M. (2009) · Bone · doi:10.1016/j.bone.2008.10.001 · Cited by 214
Ruckle, J., Jacobs, M., Kramer, W., Pearsall, A. E., Kumar, R., Underwood, K. W., Seehra, J., Yang, Y., Condon, C. H., & Sherman, M. L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081208 · Cited by 211
Heiland, G. R., Zwerina, K., Baum, W., Kireva, T., Distler, J. H., Grisanti, M., Asuncion, F., Li, X., Ominsky, M., Richards, W., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.132852 · Cited by 208
A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity
Pearsall, R. S., Canalis, E., Cornwall-Brady, M., Underwood, K. W., Haigis, B., Ucran, J., Kumar, R., Pobre, E., Grinberg, A., Werner, E. D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711263105 · Cited by 189
Horwitz, M. J., Tedesco, M. B., Gundberg, C., Garcia-Ocana, A., & Stewart, A. F. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021122 · Cited by 187
Kulkarni, N. H., Onyia, J. E., Zeng, Q., Tian, X., Liu, M., Halladay, D. L., Frolik, C. A., Engler, T., Wei, T., Kriauciunas, A., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060316 · Cited by 182
Bone Mineral Density in Sclerosteosis; Affected Individuals and Gene Carriers
Gardner, J. C., van Bezooijen, R. L., Mervis, B., Hamdy, N. A. T., Löwik, C. W. G. M., Hamersma, H., Beighton, P., & Papapoulos, S. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1235 · Cited by 178
Of mice and men: divergent risks of teriparatide-induced osteosarcoma
Subbiah, V., Madsen, V. S., Raymond, A. K., Benjamin, R. S., & Ludwig, J. A. (2010) · Osteoporosis International · doi:10.1007/s00198-009-1004-0 · Cited by 177
The activin A‐follistatin system: potent regulator of human extracellular matrix mineralization
Eijken, M., Swagemakers, S., Koedam, M., Steenbergen, C., Derkx, P., Uitterlinden, A. G., van der Spek, P. J., Visser, J. A., de Jong, F. H., Pols, H. A. P., et al. (2007) · The FASEB Journal · doi:10.1096/fj.07-8080com · Cited by 174
Wang, F.-S., Ko, J.-Y., Yeh, D.-W., Ke, H.-C., & Wu, H.-L. (2008) · Endocrinology · doi:10.1210/en.2007-0910 · Cited by 173
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000115856.54444.d6 · Cited by 159
Fracture Risk From Psychotropic Medications: A Population-Based Analysis
Bolton, J. M., Metge, C., Lix, L., Prior, H., Sareen, J., & Leslie, W. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817d5943 · Cited by 158
Sims, A. M., Shephard, N., Carter, K. W., Doan, T., Dowling, A., Duncan, E. L., Eisman, J. A., Jones, G., Nicholson, G. C., Prince, R. L., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071113 · Cited by 158
Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Cosman, F., Lane, N. E., Bolognese, M. A., Zanchetta, J., García-Hernández, P. A., Sees, K. H., Matriano, J. A., Gaumer, K., & Daddona, P. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0358 · Cited by 149
Sclerostin antibody treatment enhances metaphyseal bone healing in rats
Agholme, F., Li, X., Isaksson, H., Ke, H. Z., & Aspenberg, P. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.135 · Cited by 147
The use of parathyroid hormone in the treatment of osteoporosis
Girotra, M., Rubin, M. R., & Bilezikian, J. P. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9007-z · Cited by 136
Stewart, A. F., Cain, R. L., Burr, D. B., Jacob, D., Turner, C. H., Hock, J. M., & Drezner, M. K. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1517 · Cited by 129
Advances in osteoclast biology resulting from the study of osteopetrotic mutations
Segovia‐Silvestre, T., Neutzsky-Wulff, A. V., Sørensen, M. G., Christiansen, C., Bollerslev, J., Karsdal, M. A., & Henriksen, K. (2008) · Human Genetics · doi:10.1007/s00439-008-0583-8 · Cited by 128
Lotinun, S., Pearsall, R. S., Davies, M. V., Marvell, T. H., Monnell, T. E., Ucran, J. A., Fajardo, R. J., Kumar, R., Underwood, K. W., Seehra, J. S., et al. (2010) · Bone · doi:10.1016/j.bone.2010.01.370 · Cited by 127
Self-citationEastell, R., Nagase, S., Ohyama, M., Small, M., Sawyer, J. P. C., Boonen, S., Spector, T. D., Kuwayama, T., & Deacon, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.341 · Cited by 126
High Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5
Little, R. D., Recker, R. R., & Johnson, M. L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200209193471216 · Cited by 123
Reduced Relative Risk of Fractures Among Users of Lithium
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0258-y · Cited by 118
Parathyroid Hormone Increases β-Catenin Levels through Smad3 in Mouse Osteoblastic Cells
Tobimatsu, T., Kaji, H., Sowa, H., Naito, J., Canaff, L., Hendy, G. N., Sugimoto, T., & Chihara, K. (2006) · Endocrinology · doi:10.1210/en.2005-1627 · Cited by 117
Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits
Pennypacker, B. L., Duong, L. T., Cusick, T. E., Masarachia, P. J., Gentile, M. A., GAUTHIER, J. Y., Black, W. C., Scott, B. B., Samadfam, R., Smith, S. Y., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.223 · Cited by 110
Yakar, S., CANALIS, E. M., Sun, H., Mejía, W., Kawashima, Y., Nasser, P. R., Courtland, H., Williams, V., Bouxsein, M., Rosen, C. J., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090226 · Cited by 108
Saidak, Z., Brazier, M., Kamel, S., & Mentaverri, R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058784 · Cited by 105
Sugatani, T., Alvarez, U., & Hruska, K. A. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10613 · Cited by 102
The search for calcium receptor antagonists (calcilytics)
Nemeth, E. F. (2002) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0290015 · Cited by 102
Suzuki, A., Ozono, K., Kubota, T., Kondou, H., Tachikawa, K., & Michigami, T. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21626 · Cited by 101
Wang, F.-S., Ko, J.-Y., Lin, C.-L., Wu, H.-L., Ke, H.-J., & Tai, P.-J. (2007) · Bone · doi:10.1016/j.bone.2006.09.004 · Cited by 100
Yao, W., Cheng, Z., Shahnazari, M., Dai, W., Johnson, M. L., & Lane, N. E. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090719 · Cited by 97
Horwitz, M. J., Tedesco, M. B., García-Ocaña, A., Sereika, S. M., Prebehalla, L., Bisello, A., Hollis, B. W., Gundberg, C. M., & Stewart, A. F. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0233 · Cited by 94
Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys
Jerome, C. P., Missbach, M., & Gamse, R. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1529-x · Cited by 87
Kumar, S., Matheny, C. J., Hoffman, S. J., Marquis, R. W., Schultz, M., Liang, X. G., Vasko, J. A., Stroup, G. B., Vaden, V. R., Haley, H., et al. (2009) · Bone · doi:10.1016/j.bone.2009.09.028 · Cited by 82
Fitzpatrick, L. A., Dabrowski, C., Cicconetti, G., Gordon, D. N., Papapoulos, S. E., Bone, H. G., & Bilezikian, J. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2855 · Cited by 80
Guo, J., Liu, M., Yang, D., Bouxsein, M., Thomas, C. C., Schipani, E., Bringhurst, F. R., & Kronenberg, H. M. (2010) · Endocrinology · doi:10.1210/en.2009-1494 · Cited by 76
Gambardella, A., Nagaraju, C. K., O'Shea, P. J., Mohanty, S. T., Kottam, L., Pilling, J. E., Sullivan, M., Djerbi, M., Koopmann, W., Croucher, P. I., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.266 · Cited by 70
Secreted frizzled related protein 1 is a target to improve fracture healing
Gaur, T., Wixted, J. J., Hussain, S., O’Connell, S. L., Morgan, E. F., Ayers, D. C., Komm, B. S., Bodine, P. V. N., Stein, G. S., & Lian, J. B. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21747 · Cited by 67
One Year of Alendronate After One Year of Parathyroid Hormone (1???84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T. F., Lang, T., McGowan, J., & Rosen, C. J. (2005) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000193859.78235.fe · Cited by 64
Inhibition of glycogen synthase kinase-3β attenuates glucocorticoid-induced bone loss
Wang, F., Ko, J., Weng, L., Yeh, D., Ke, H.-J., & Wu, S.-L. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.09.009 · Cited by 62
Lithium use and the risk of fractures
Wilting, I., de Vries, F., Thio, B., Cooper, C. C., Heerdink, E. R., Leufkens, H. G. M., Nolen, W. A., Egberts, T. C. G., & van Staa, T. P. (2006) · Bone · doi:10.1016/j.bone.2006.12.055 · Cited by 61
Tian, X., Setterberg, R. B., Li, X., Pászty, C., Ke, H. Z., & Jee, W. S. S. (2010) · Bone · doi:10.1016/j.bone.2010.05.032 · Cited by 56
John, M. R., Widler, L., Gamse, R., Buhl, T., Seuwen, K., Breitenstein, W., Bruin, G. J. M., Belleli, R., Klickstein, L. B., & Kneissel, M. (2011) · Bone · doi:10.1016/j.bone.2011.04.007 · Cited by 49
Hollick, R. J., & Reid, D. M. (2011) · Menopause international · doi:10.1258/mi.2011.011014 · Cited by 44
Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys
Jerome, C. P., Missbach, M., & Gamse, R. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1593-2 · Cited by 44
Widler, L., Altmann, E., Beerli, R., Breitenstein, W., Bouhelal, R., Buhl, T., Gamse, R., Gerspacher, M., Halleux, C. M., John, M. R., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901811v · Cited by 40
Cho, H. Y., Choi, H. J., Sun, H. J., Yang, J., An, J. H., Cho, S. W., Kim, S. W., Kim, S. Y., Kim, J. E., & Shin, C. S. (2010) · Bone · doi:10.1016/j.bone.2010.05.010 · Cited by 38
Drake, M. T., Srinivasan, B., Mödder, U. I., Ng, A. C., Undale, A. H., Roforth, M. M., Peterson, J. M., McCready, L. K., Riggs, B. L., & Khosla, S. (2011) · Bone · doi:10.1016/j.bone.2011.05.003 · Cited by 38
Comite, G. D., & Morganti, A. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328341a429 · Cited by 29
Nagase, S., Ohyama, M., Hashimoto, Y., Small, M., Kuwayama, T., & Deacon, S. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011399080 · Cited by 28
Spiro, A. S., Beil, F. T., Schinke, T., Schilling, A. F., zu Eulenburg, C., Rueger, J. M., & Amling, M. (2010) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3181dc59e4 · Cited by 25
Cited by
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519
Osteoporosis treatment: recent developments and ongoing challenges
Khosla, S., & Hofbauer, L. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30188-2 · Cited by 1,019
Oxidative stress in bone remodeling: role of antioxidants
Domazetovic, V (2017) · Clinical Cases in Mineral and Bone Metabolism · doi:10.11138/ccmbm/2017.14.1.209 · Cited by 758
Parathyroid hormone: anabolic and catabolic actions on the skeleton
Silva, B. C., & Bilezikian, J. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.005 · Cited by 557
How smart do biomaterials need to be? A translational science and clinical point of view
Holzapfel, B. M., Reichert, J. C., Schantz, J.-T., Gbureck, U., Rackwitz, L., Nöth, U., Jakob, F., Rudert, M., Groll, J., & Hutmacher, D. W. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.009 · Cited by 552
Metadata
- Authors
- Baron, R., & Hesse, E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-02
- Volume
- 97
- Issue
- 2
- Pages
- 311-325
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2104357139
- Cited by
- 320
- References
- 103
- FWCI
- 41.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.